Late Adverse Cardiorenal Events of Catheter Procedure-Related Acute Kidney Injury After Transcatheter Aortic Valve Implantation.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 10 2020
Historique:
received: 28 04 2020
revised: 13 07 2020
accepted: 17 07 2020
pubmed: 17 8 2020
medline: 13 11 2020
entrez: 17 8 2020
Statut: ppublish

Résumé

Data regarding the longitudinal effect of catheter procedure-related acute kidney injury (AKI) on clinical outcomes are limited. This study aimed to assess the late adverse cardiorenal events of AKI following transcatheter aortic valve implantation (TAVI). A total of 2,518 patients who underwent TAVI, excluding in-hospital deaths, were enrolled from the Japanese multicenter registry. The definition of AKI was determined using the Valve Academic Research Consortium-2 criteria. The incidence, predictors, major adverse renal and cardiac events (MARCE), and all-cause mortality of AKI were evaluated. MARCE included readmission for renal and heart failure (HF), hemodialysis requirement, and cardiovascular-renal death during the follow-up period. The incidence of AKI was 9.7% in the entire cohort. The significant predictive factors of AKI were men, diabetes mellitus, hypertension, chronic kidney disease, low albumin, overdose of contrast media, nontransfemoral approach, transfusion, vascular complications, and new pacemaker implantation. The rates of HF readmission and future hemodialysis were significantly higher in patients with AKI than in those without AKI (19.7% vs 9.0%, p <0.001, 3.3% vs 0.4%, p <0.001, respectively). Cox regression multivariate analysis showed that AKI occurrence was an independent predictive factor for the incremental risk of both MARCE and late mortality up to 4 years (hazard ratio [HR] 1.59, 95% confidence interval [CI] 0.75 to 1.20, p <0.001, HR 2.18, 95% CI 1.70 to 2.79; p <0.001, respectively). In conclusion, AKI occurrence was significantly associated with late adverse cardiorenal events after TAVI. Adequate clinical management can be expected to reduce AKI-related late phase cardiorenal damage even after successful TAVI.

Identifiants

pubmed: 32798043
pii: S0002-9149(20)30775-X
doi: 10.1016/j.amjcard.2020.07.041
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

89-97

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Yuya Adachi (Y)

Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan.

Masanori Yamamoto (M)

Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan; Department of Cardiology, Nagoya Heart Center, Nagoya, Japan. Electronic address: masa-nori@nms.ac.jp.

Tetsuro Shimura (T)

Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan.

Ryo Yamaguchi (R)

Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan.

Ai Kagase (A)

Department of Cardiology, Nagoya Heart Center, Nagoya, Japan.

Takahiro Tokuda (T)

Department of Cardiology, Nagoya Heart Center, Nagoya, Japan.

Satoshi Tsujimoto (S)

Department of Cardiology, Nagoya Heart Center, Nagoya, Japan.

Yutaka Koyama (Y)

Department of Cardiology, Nagoya Heart Center, Nagoya, Japan.

Toshiaki Otsuka (T)

Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan; Center for Clinical Research, Nippon Medical School Hospital, Tokyo, Japan.

Fumiaki Yashima (F)

Department of Cardiology, Saiseikai Utsunomiya Hospital, Tochigi, Japan; Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Norio Tada (N)

Department of Cardiology, Sendai Kosei Hospital, Sendai, Japan.

Toru Naganuma (T)

Department of Cardiology, New Tokyo Hospital, Chiba, Japan.

Motoharu Araki (M)

Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Yokohama, Japan.

Futoshi Yamanaka (F)

Department of Cardiology, Shonan Kamakura General Hospital, Kanagawa, Japan.

Shinichi Shirai (S)

Department of Cardiology, Kokura Memorial Hospital, Kokura, Japan.

Kazuki Mizutani (K)

Department of Cardiology, Osaka City General Hospital, Osaka, Japan.

Minoru Tabata (M)

Department of Cardiovascular Surgery, Tokyo Bay Urayasu-Ichikawa Medical Center, Chiba, Japan.

Hiroshi Ueno (H)

Department of Cardiology, Toyama University Hospital, Toyama, Japan.

Kensuke Takagi (K)

Department of Cardiology, Ogaki Municipal Hospital, Gifu, Japan.

Yusuke Watanabe (Y)

Department of Cardiology, Teikyo University School of Medicine, Tokyo, Japan.

Kentaro Hayashida (K)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH